Short answer
Thermo Fisher Scientific (TMO) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results announced October 21, 2026.
Thermo Fisher Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced October 21, 2026
- Reporting period ended September 26, 2026
- Full earnings release furnished as Exhibit 99.1, containing the substantive financial details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $12.14B, up 9%, with 6% organic growth, indicating broad underlying demand beyond acquisitions and divestitures
- GAAP diluted EPS $4.64, up 9%; adjusted EPS $6.68, up 15%, showing stronger earnings growth after acquisition-related adjustments
- GAAP operating margin 18.6% vs 17.4%; adjusted margin 24.5% vs 23.3%, reflecting operating leverage and execution
- Nine-month free cash flow $4.62B vs $3.32B, supporting acquisitions, debt management, buybacks and dividends
- Q3 capital deployment included microbiology divestiture completion; nine-month acquisitions totaled $8.88B and share repurchases $4.00B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Thermo Fisher Scientific 8-K filings
Get the next TMO 8-K as it lands
Follow TMO for push alerts, or ask the research agent what this filing means.